Friday - February 27, 2026
Early Study Results From Johnson & Johnson Show Promising Antitumor Activity With Combination of Pasritamig and Docetaxel in Advanced Prostate Cancer
February 27, 2026
RARITAN, New Jersey, Feb. 27 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 26, 2026:

* * *

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3

Data highlight the potential of this first-in-class next . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products